Strontium Ranelate

Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling[1][2].

Product Specifications

CAS Number

[135459-87-9]

Product Name Alternative

Distrontium renelate; S12911

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CaSR

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Strontium-Ranelate.html

Purity

99.99

Solubility

0.1 M HCl : 17.5 mg/mL (ultrasonic; adjust pH to 3 with HCl) |H2O : 2 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O[Sr]OC(C1)=O)C2=C1C(C#N)=C(N3CC(O[Sr]OC(C3)=O)=O)S2

Molecular Formula

C12H6N2O8SSr2

Molecular Weight

513.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008 Jan;42 (1) :129-38. Epub 2007 Sep 12.|[2]Marie PJ. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol. 2006 Jun;18 Suppl 1:S11-5.